LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month. Read about what it’s achieved so far, and what’s next for the partnership. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab282-two-years-of-drug-discovery-impact-5751